India, July 17 -- Shares of REGENXBIO Inc. (RGNX) fell nearly 20% after the company announced it has priced a $100 million public offering of common stock and pre-funded warrants.
The offering includes 10,003,889 shares of common stock at $9.00 per share and 1,111,111 pre-funded warrants at $8.9999 per warrant, before underwriting discounts and commissions. Gross proceeds are expected to total about $100 million, with closing scheduled for July 20, 2026, subject to customary closing conditions.
REGENXBIO has also granted underwriters a 30-day option to purchase up to 1,667,250 additional shares at the public offering price. Morgan Stanley, J.P. Morgan, Leerink Partners and Mizuho are acting as joint book-running managers.
googletag.cmd.p...